Scinai Immunotherapeutics Ltd. (SCNI) Financial Analysis & Valuation | Quarter Chart
Scinai Immunotherapeutics Ltd. (SCNI)
SCNIPrice: $0.71
Fair Value: 🔒
🔒score
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with M... more
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing... more
Description
Shares
| Market Cap | $934,436 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IL | CEO | Amir Reichman |
| IPO Date | 2015-05-11 | CAGR | — |
| Employees | 31 | Website | www.scinai.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SCNI chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.35M | P/E Ratio | 0.18 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 0.01 | P/B Ratio | 0.01 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $4 | EPS Growth 1Y | 316033.33% |
| EPS Growth 3Y | -87.99% | EPS Growth 5Y | -96.05% |
| Revenue Growth 1Y | 177.94% | Gross Margin | -1.14% |
| Operating Margin | -5.56% | Profit Margin | -6.34% |
| ROE | -0.89% | ROA | -0.67% |
| ROCE | -0.72% | Current Ratio | 0.71 |
| Quick Ratio | 0.71 | Cash Ratio | 0.47 |
| Debt/Equity | 0.3 | Interest Coverage | -29.94 |
| Altman Z Score | -15.93 | Piotroski Score | 5 |